About Us
Regulating Radiation Beams to treat cancer:
Exelar Medical Corporation, a privately-held biotechnology company, is developing a device for use with high-energy-photon linear accelerators used by radiation oncology departments. The product controls the amount of energy absorbed at different points inside the body along the length of the treatment beam. For instance, it allows the photon beam to deliver a high dose to a lung tumor while curtailing the energy before and after the tumor to protect nearby tissue.
It is hoped that Exelar's process will assist in treating malignancies located near radiation-sensitive regions like the lung, prostate, head and neck. Current technology can only control an accelerator beam's cross-section and intensity and reduces healthy tissue exposure by varying the angle of entry into the patient. Present methods generally cannot control the radiation dose longitudinally (i.e.along) a given beam.
Exelar received early-stage funding in March, 2004. The company is planning a Premarket Approval/510(k) application to the Food and Drug Administration.
